Table 1.

Characteristics of some metabolic pathway blockers in influenza infection

Agent	Target	Outcome	Model	Reference
BEZ235	PI3K/mTOR	Reconstitution of metabolic status and decreased viral replication	In vivo	[9]
Hochuekkito	Effect on mitochondrial and glycolysis	Ameliorates metabolism and intensifies the symptoms	In vitro	[160]
Simvastatin	Sterol synthesis	Decreased influenza replication and cytokine production	In vitro	[161]
DADA	Pyruvate dehydrogenase kinase	Suppresses cytokine storm and viral replication	In vivo	[94]
MJWQH	amino acid, fatty acid and arachidonic acid pathway	Improved weight loss, lung index, biomarkers and inflammatory mediators such as prostaglandin E2	In vivo	[162]
Bezafibrate	Carnitine palmitoyltransferase II	Restores the ATP levels in cells and intensifies the symptoms	In vivo	[110]
AM580	Sterol regulatory element binding protein (SREBP) pathways	Inhibited influenza virus replication through interference with SREBP paths	In vivo	[105]

DADA Diisopropylamine dichloroacetate, MJWQH Modified Jiu Wei Qiang Huo